The Indian IPO market continues to be dynamic in 2025, offering investors exposure to companies across diverse sectors. One of the most talked-about upcoming issues is Anthem Biosciences Limited, a leading player in the contract research and manufacturing space. With India rising as a global hub for pharma outsourcing, the company’s public offering is being closely tracked by both institutional and retail investors.
The Anthem IPO 2025 opens with a price band of ₹540–₹570 per share, and the lot size is set at 26 shares. This issue is structured as a pure Offer for Sale (OFS) worth ₹3,395 crore, and the shares are proposed to be listed on both BSE and NSE.
So, should you apply for this IPO or stay on the sidelines? Let’s explore the business model, financials, industry trends, strengths, challenges, and the overall investor outlook.
Incorporated in 2006 and headquartered in Bangalore, Karnataka, Anthem Biosciences is a full-service Contract Research and Manufacturing Services (CRAMS) company. Over the years, it has evolved into a fully integrated CRDMO (Contract Research, Development, and Manufacturing Organization), providing a wide range of solutions across the pharmaceutical and biopharmaceutical value chain.
Their core capabilities include:
With a focus on innovation and global compliance, Anthem serves several multinational pharma and biotech companies. Its facilities, based in Karnataka and Tamil Nadu, are designed to meet international standards, including compliance with US FDA, EMA, and WHO-GMP norms.
The company is promoted by a team of industry experts including Ajay Bhardwaj, Ganesh Sambasivam, K. Ravindra Chandrappa, and Ishaan Bhardwaj. Over the years, Anthem has built a solid reputation for delivering high-complexity solutions in both discovery and development domains.
The Indian CRDMO market is currently in a high-growth phase both globally and in India. According to a report by CRISIL:
Key structural and macro-level drivers include:
This macro environment is highly favorable for players like Anthem, who already have diversified capabilities across both small and large molecule services.
Anthem stands out as one of the few Indian CRDMOs offering end-to-end capabilities—from drug discovery and development to manufacturing—for both small molecules and biologics. This full-stack model supports its leadership in the evolving Indian CRDMO market.
In FY2025, the company posted:
These numbers place Anthem ahead of most Indian and global peers in the same segment.
Five of its top commercialized molecules contribute to products with end-market sales of USD 11.3 billion (2024). What adds value is that these molecules are protected by patents till 2031–2039, providing revenue security and insulation from early competition.
Anthem has invested early in pioneering technologies that are in high demand globally:
These advanced capabilities are positioning the company as a go-to partner for high-end biopharma development.
With 142,000 liters of fermentation capacity—expected to grow to 182,000 liters—Anthem leads the Indian CRDMO space. This is over 6x higher than its nearest Indian peer, offering unmatched scale for microbial and enzyme-based manufacturing.
The company hit the ₹1,000 crore revenue milestone in just 14 years, the fastest among comparable Indian players. This shows management execution capability and consistent demand traction.
No IPO is without risks, and here are some red flags that investors must factor in before applying:
With aggressive capacity expansion, there is a possibility that future demand might not keep pace, leading to lower plant utilization, which could impact cost-efficiency and margins.
As biopharma technologies become more specialized, the limited availability of trained personnel could affect project timelines and service quality.
Anthem operates in a highly regulated environment. Any delay or non-compliance with global standards such as US FDA, EMA, or WHO-GMP could disrupt operations and dent reputation.
A large share of revenue comes from a few major clients. Losing even one key customer could significantly affect topline and margins.
Biopharma development is inherently risky. The average cost to develop a new drug exceeds USD 1 billion, and it can take up to 13.5 years to reach market. This makes revenue timing unpredictable and adds volatility to the CRDMO business model.
Anthem Biosciences offers a unique opportunity to invest in a fast-scaling biopharma service provider that’s positioned at the crossroads of innovation, outsourcing, and global regulatory compliance.
It has clearly demonstrated:
However, this is a 100% OFS (Offer for Sale) issue—no new capital is coming into the company. This may be seen as a partial exit by promoters and doesn’t directly fuel the company’s next leg of growth.
IPO Price Band: ₹540 to ₹570 per share
Lot Size: 26 shares
Issue Type: Offer for Sale (₹3,395 crore)
Listing on: BSE and NSE
Anthem is a rare Indian player with deep R&D, high-tech capabilities, a patent-protected portfolio, and scale that positions it to lead India’s rise in the global CDMO space. If you’re a high-conviction investor with a multi-year view, this could be a valuable addition to your portfolio.
Rating: Neutral-to-Positive (For long-term investors)
Disclaimer: This article is intended for informational purposes only and does not constitute investment advice or a recommendation to apply for the IPO. Please read the Draft Red Herring Prospectus (DRHP) and consult a SEBI-registered financial advisor before making any investment decisions. For detailed disclosures and risk factors, refer to the official filings available on the SEBI website.
https://uat.jainam.in/wp-content/uploads/2024/11/Disclosure-and-Disclaimer_Research-Analyst.pdf
Join our 3 Cr+ happy customers
Know the mind behind this article
Open your free Demat account in minutes or explore partnership opportunities with Jainam.
Get the link to download the App
